Access Circuit Thrombosis

A drug-coated balloon was superior to percutaneous transluminal angioplasty at 1 year for primary patency and clinically driven target lesion revascularization in patients with de novo or restenotic arteriovenous fistula lesions, according to new data from the IN.PACT AV Access study.